CHANGING THE WAY HEART FAILURE IS TREATED. VAD Therapy
|
|
- Darleen King
- 5 years ago
- Views:
Transcription
1 CHANGING THE WAY HEART FAILURE IS TREATED VAD Therapy
2 VAD THERAPY IS BECOMING AN ESSENTIAL PART OF HEART FAILURE PROGRAMS AROUND THE WORLD. Patients with advanced heart failure experience an impaired quality of life and the significant personal and economic impact of recurrent hospitalizations. A substantial number of patients who could benefit from this therapy are not currently being referred or considered for LVAD therapy. 1 Ventricular assist devices (VADs) are transforming the treatment of patients with advanced heart failure. In fact, few advancements in healthcare today have a greater potential to impact heart failure than VADs. VAD therapy is part of the field of Mechanical Circulatory Support (MCS). VADs are mechanical devices designed to help a weakened heart pump blood throughout the body by moving blood from the left ventricle and pumping it into the ascending aorta. VADs positively impact cardiac output and help alleviate the symptoms of heart failure. HeartWare HVAD Ventricular Assist Device
3 WHEN MANAGING PATIENTS WITH ADVANCED HEART FAILURE, CONSIDER DISCUSSING REFERRAL FOR VAD THERAPY WHILE THEY STILL HAVE TIME TO MAKE A CHOICE. If your patient is persistently symptomatic and has one or more of the C.H.O.I.C.E. risk factors, he or she may be a candidate for VAD therapy. From the first consideration of a VAD, emphasis should be placed on the anticipated differences between ongoing medical therapy and VADs with respect to both survival and quality of life. These discussions should occur before consideration of continuous outpatient inotropic infusions for hemodynamic support of deteriorating clinical status. 2 C H O I C E CLASS IIIB / IV NYHA classification symptoms with an ejection fraction (EF) <30% 3 HOSPITALIZATION Each subsequent hospitalization for heart failure is associated with a significant further reduction in survival 1 OPTIMAL Medical management not effective 3,4 INOTROPE Therapy being considered or initiated 4 CLINICAL Parameters worsening 5 EVOLVING Or progressing organ dysfunction 3,4 SYMPTOMS TO WATCH FOR: Shortness of breath on mild exertion/breathless at rest 5 Low six-minute walk test distance (<300 m) 3 Inability to perform an exercise test 3 Inability to climb two flights of stairs Inability to walk two blocks Increased diuretic requirement 3 Intolerance to neurohormonal antagonists 3 (ACEi/ARB/BB) Hypotension 3 CRT non-responder/not indicated 6 Increasing plasma BNP or NTproBNP levels, despite adequate heart failure treatment 7
4 MEDIAN SURVIVAL DECREASES AFTER EACH HEART FAILURE- RELATED HOSPITALIZATION MEDIAN SURVIVAL (YEARS) st Hospitalization (n=14,374) 2 nd Hospitalization (n=3,358) 3 rd Hospitalization (n=1,123) 4 th Hospitalization (n=417) AVERAGE AGE OF HEART FAILURE HOSPITALIZATION IN COMMUNITY = YEARS OBSERVED MORTALITY BY NUMBER OF THE SPECIFIED RISK FACTORS 7 SURVIVAL RATES (%) Risk Factors 1 Risk Factor 2 Risk Factors 3-5 Risk Factors YEARS One or more of the following risk factors should trigger generalist to refer to an advanced heart failure center: 7 Systolic blood pressure 90 mm Hg Creatinine 160 μmol/l Hemoglobin 120 g/l No treatment with renin-angiotensin system antagonist No treatment with beta-blocker NO. AT RISK 0 RISK FACTORS
5 VADS ADDRESS A NEED There is a shortage of hearts heart transplantation rates remain steady, yet demand continues to rise with more patients waiting for a transplant. HEART FAILURE STATISTICS 1 in 5 At 40 years of age, the lifetime risk of developing heart failure for both men and women is 1 in 5. 8,13 49% 49% of the people who are on the heart transplantation wait list have been waiting for over a year % 50% 3,100 Projections show that by 2030, the prevalence of heart failure in the U.S. is projected to rise by 46%, resulting in 8 million people with heart failure. 12 Survival after heart failure diagnosis has improved over time; however, the death rate remains high: 50% of people diagnosed with heart failure will die within five years. 8 On any given day, there are 3,100 people in the United States who are on the heart transplant wait list. 12 MANY HEART FAILURE PATIENTS WAITING FOR A DONOR HEART BECOME INOTROPE- DEPENDENT. 8
6 GLOBAL ENDORSEMENT A simple solution that can transform patients lives. VAD therapy does not cure heart failure, but the data and trends demonstrate that VAD therapy may offer a C.H.O.I.C.E. for your advanced heart failure patients. 51% of heart transplant patients worldwide are bridge-to-transplant with a VAD. 9 VAD therapy has been globally endorsed as an option by the: American Heart Association (AHA) 3 European Society of Cardiology (ESC) 4 International Society for Heart and Lung Transplantation (ISHLT) 14 A decreasing number of patients on the heart transplant waiting list die because of the availability of VAD therapy. However, a significant percentage of that number dies of progressive heart failure without the use of VADs. 1
7 Early referral equals a C.H.O.I.C.E. for your patients. Despite optimal medical management, your patient continues to be readmitted to the hospital for acute heart failure symptoms, becoming a frequent flyer and potentially inotrope-dependent. Of those, 50% who have three hospital stays will die within one year. 3 These patients may be good candidates for referral to an advanced heart failure center for assessment. KEY FACTS: Heart failure is a serious disease that affects an estimated 26 million patients worldwide 10 Heart failure is the leading cause of hospitalization in the U.S. and Europe 10 Heart failure has the highest readmission rate of any diagnosis related group, averaging 20% at 1 month and 50% at 6 months 1 An estimated 10% of heart failure patients have an advanced condition 11 with symptoms, such as shortness of breath, even while resting Worldwide 50,000 candidates are waiting for heart transplantation, 12 yet only approximately 4,000 heart transplants are performed each year 9
8 References 1. Miller, L, et al. Is left ventricular assist device therapy underutilized in the treatment of heart failure? Circulation. 2011;123: Stewart, G, et al. Who wants a left ventricular assist device for ambulatory heart failure? Early insights from the MEDAMACS screening pilot. J Heart Lung Transplant. 2015;34: Peura, J, et al. AHA. Recommendations for the use of mechanical circulatory support: device strategies and patient selection.2012;126: Ponikowski, P, et al ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Eur Heart J. 2016;37: Thorvaldsen, T, T, et et al. al. Triage of of patients with with moderate to severe to severe heart heart failure failure who who should should be referred be referred to a heart to a heart failure failure center. center. J Am Coll J Am Cardiol. Coll Cardiol. 2014;63: Daubert, 63: J, et al EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: Implant and follow-up 6. recommendations Daubert, J, et al and EHRA/HRS management. expert Europace. consensus 2012;14: statement on cardiac resynchronization therapy in heart failure: Implant and follow-up 7. Banner, recommendations N, et al. UK Guidelines and management. for referral Europace. and assessment 2012;14: of adults for heart transplantation. Heart. 2011;97: Go, Banner, A, et N, al. et AHA al. UK statistical Guidelines update. for referral Heart and disease assessment and stroke of statistics adults for - heart 2013 transplantation. update. A report Heart. from the 2011;97: American Heart Association. 8. Circulation. Go, A, et al. AHA 2013;127:e199-e201. statistical update. Heart disease and stroke statistics update. A report from the American Heart Association. 9. Lund, Circulation. L, et al. 2013;127:e199-e201. For the International Society for Heart and Lung Transplantation, The Registry of the International Society for Heart and Lung 9. Transplantation. Lund, LH et al. The Thirty-second Registry of the Official International Adult Heart Society Transplantation for Heart and Report Lung -- Transplantation: 2015; Focus Theme: Thirty-third Early Adult Graft Failure, Heart Transplantation J Heart Lung Transplant. Report-2016; 2015;34: Focus Theme: Primary Diagnostic Indications for Transplant. JHLT.2016 Oct, 35(10): Ponikowski, Ambrosy, P, et P, et al. al. The Heart global failure: health preventing and economic disease burden and death of hospitalizations worldwide.esc for Heart heart Failure failure. 2014; Lessons 1:4 25. learned from hospitalized heart failure 11. Ambrosy, registries. P, J Am et al. Coll The Cardiol. global health 2014;63:1123 and economic burden of hospitalizations for heart failure. Lessons learned from hospitalized heart failure 11. registries. J Am Coll Cardiol. 2014;63: Accessed April 3, HealthResearchFunding.org. Accessed April 3, Accessed April 3, HealthResearchFunding.org. Heidenreich, P, et al. AHA Policy Accessed Statement. April Forecasting 3, the impact of heart failure in the United States. A policy statement from the American 14. Stehlik, Heart Association. J, et al. The Circ Registry Heart of Fail. the 2013;6: International Society for Heart and Lung Transplantation: 29th official adult heart transplant report J Feldman, Heart Lung D, et Transplant. al. The ;31: International Society for Heart and Lung Transplantation Guidelines for Mechanical Circulatory Support: Executive Summary. 15. Heidenreich, J Heart Lung P, Transplant et al. AHA 2013;32: Policy Statement. Forecasting the impact of heart failure in the United States. A policy statement from the American Heart Association. Circ Heart Fail. 2013;6: Feldman, D, et al. The 2013 International Society for Heart and Lung Transplantation Guidelines for Mechanical Circulatory Support: Executive Summary. J Heart Lung Transplant 2013;32: Brief Statement: HeartWare HVAD System Indications The HeartWare Ventricular Assist System is indicated for use as a bridge to cardiac transplantation in patients who are at risk of death from refractory end-stage left ventricular heart failure. The HeartWare System is designed for in-hospital and out-of-hospital settings, including transportation via fixed wing aircraft or helicopter. Contraindications The HeartWare System is contraindicated in patients who cannot tolerate anticoagulation therapy. Warnings/Precautions Proper usage and maintenance of the HVAD System is critical for the functioning of the device. Never disconnect from two power sources at the same time (batteries or power adapters) since this will stop the pump, which could lead to serious injury or death. At least one power source must be connected at all times. Always keep a spare controller and fully charged spare batteries available at all times in case of an emergency. Do not expose batteries to excessive shock or vibration since this may affect battery operation. Do not grasp the driveline cable as this may damage the driveline. Do not pull, kink or twist the driveline or the power cables, as these actions may damage the driveline. Special care should be taken not to twist the driveline including while sitting, getting out of bed, adjusting the controller or power sources, or when using the shower bag. Do not disconnect the driveline from the controller or the pump will stop. If this happens, reconnect the driveline to the controller as soon as possible to restart the pump. Potential complications Implantation of a Ventricular Assist Device (VAD) is an invasive procedure requiring general anesthesia, a median sternotomy, a ventilator and cardiopulmonary bypass. There are numerous risks associated with this surgical procedure and the therapy including but not limited to, death, stroke, device malfunction, peripheral and device-related thromboembolic events, bleeding, infection, hemolysis and sepsis. Refer to the Instructions for Use for detailed information regarding the implant procedure, indications, contraindications, warnings, precautions and potential adverse events prior to using this device. The IFU can be found at Caution: Federal law (USA) restricts these devices to sale by or on the order of a physician. Medtronic NW 60th Ave Miami Lakes, FL USA Telephone: (305) Fax: (954) heartware.com US1212 Rev01 Medtronic Minneapolis, MN. All Rights Reserved. Printed in USA. 04/2017 HeartWare, HVAD, Medtronic and the Medtronic logo are registered trademarks of Medtronic.
QUICK REFERENCE HEARTWARE HVAD PUMP FLOW INDEX
QUICK REFERENCE HEARTWARE HVAD PUMP FLOW INDEX LOW PULSATILITY, LOW FLOW HVAD waveforms do NOT conform to a single, classic appearance, and are not intended for diagnostic purposes. Waveforms represent
More informationAUTOLOGS TM ATLAS ON DEMAND DATA WITH EVERY PATIENT VISIT
AUTOLOGS TM ATLAS ON DEMAND DATA WITH EVERY PATIENT VISIT Introduction The Autologs Atlas will guide your introduction to our new Autologs service and the information recorded by the HeartWare HVAD TM
More informationDestination Therapy SO MUCH DATA IN SUCH A SMALL DEVICE. HeartWare HVAD System The ONLY intrapericardial VAD approved for DT.
DT Destination Therapy SO MUCH DATA IN SUCH A SMALL DEVICE. HeartWare HVAD System The ONLY intrapericardial VAD approved for DT. ONLY WE HAVE THIS BREADTH OF CLINICAL EVIDENCE TO SUPPORT DESTINATION THERAPY.
More informationPROVEN. TRUSTED. COMMITTED. HeartWare HVAD System
PROVEN. TRUSTED. COMMITTED. HeartWare HVAD System PROVEN. TRUSTED. COMMITTED. 42% of all heart transplant patients worldwide are bridge to transplant with a VAD. 1 Our commitment to advance the treatment
More informationHEARTWARE HVAD WAVEFORM APP INSTRUCTIONS
HEARTWARE HVAD WAVEFORM APP INSTRUCTIONS TABLE OF CONTENTS Welcome... 3 HVAD Waveforms 1. Characteristics... 4 2. Theory of Operation... 5 3. Ao & LV Pressure... 6 4. HQ Curve... 7 5. PV Loops... 8 Home
More informationIs it time to consider a HEARTMATE LEFT VENTRICULAR ASSIST DEVICE (LVAD)?
Is it time to consider a HEARTMATE LEFT VENTRICULAR ASSIST DEVICE (LVAD)? A treatment for advanced heart failure. LAURA HeartMate II LVAD Recipient What is HEART FAILURE? Heart failure sometimes called
More informationLIVING A MORE ACTIVE LIFE. with the HeartMate 3 LVAD for the treatment of advanced heart failure RON. Recipient
LIVING A MORE ACTIVE LIFE with the HeartMate 3 LVAD for the treatment of advanced heart failure RON HeartMate 3 LVAD Recipient What is HEART FAILURE? Heart failure sometimes called a weak heart occurs
More informationModern Left Ventricular Assist Devices (LVAD) : An Intro, Complications, and Emergencies
Modern Left Ventricular Assist Devices (LVAD) : An Intro, Complications, and Emergencies ERIC T. ROME D.O. HEART FAILURE, MECHANICAL ASSISTANCE AND TRANSPLANTATION CVI Left Ventricular Assist Device An
More informationMechanical Circulatory Support in the Management of Heart Failure
Mechanical Circulatory Support in the Management of Heart Failure Feras Bader, MD, MS, FACC Associate Professor of Medicine Director, Heart Failure and Transplant Cleveland Clinic Abu Dhabi Chairman, Heart
More informationWHAT S NEW IN HEART FAILURE
WHAT S NEW IN HEART FAILURE Drugs, Devices and Diagnostics John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine Eastern Virginia Medical School
More informationVentricular Assist Device: Are Early Interventions Superior? Hamang Patel, MD Section of Cardiomyopathy & Heart Transplantation
Ventricular Assist Device: Are Early Interventions Superior? Hamang Patel, MD Section of Cardiomyopathy & Heart Transplantation Objectives Current rationale behind use of MCS Patient Selection Earlier?
More informationLessons learned from ENDURANCE, ROADMAP, MedaMACS, and how to go forward?
Lessons learned from ENDURANCE, ROADMAP, MedaMACS, and how to go forward? Mark S. Slaughter, MD Professor and Chair Department of Cardiovascular and Thoracic Surgery University of Louisville What could
More informationHeart Failure Medical and Surgical Treatment
Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February
More informationBridge to Heart Transplantation
Bridge to Heart Transplantation Ulf Kjellman MD, PhD Senior Consultant Surgeon Heart Centre KFSH&RC 1 Disclosure Appointed for Proctorship by Thoratec/St.Jude/Abbott 2 To run a full overall covering transplant
More informationMechanical assist patient selection, device selection, and outcomes
Mechanical assist patient selection, device selection, and outcomes Josef Stehlik, MD, MPH Associate Professor of Medicine Medical Director, Heart Transplant Program University of Utah School of Medicine
More informationAbby Woods, DNP, FNP Southern Illinois Healthcare Supportive Care Program END OF LIFE ISSUES IN THE CARE OF CARDIAC PATIENTS
Abby Woods, DNP, FNP Southern Illinois Healthcare Supportive Care Program END OF LIFE ISSUES IN THE CARE OF CARDIAC PATIENTS Objectives Describe a team approach in the setting of critical illness Differentiate
More informationWhen to implant VAD in patients with heart transplantation indication. Aldo Cannata Dept of Cardiac Surgery Niguarda Ca Granda Hospital Milano
When to implant VAD in patients with heart transplantation indication Aldo Cannata Dept of Cardiac Surgery Niguarda Ca Granda Hospital Milano LVAD strategies In waiting list? Goal Bridge to transplant
More informationHEARTMATE 3 LVAD WITH FULL MAGLEV FLOW TECHNOLOGY THEIR FUTURE STARTS WITH YOU
HEARTMATE 3 WITH FULL MAGLEV FLOW TECHNOLOGY THEIR FUTURE STARTS WITH YOU HEARTMATE 3 with Full MagLev Flow Technology HEARTMATE 3 DELIVERS UNPRECEDENTED * SURVIVAL AND SAFETY OUTCOMES **1 LANDMARK SURVIVAL
More informationThe Counter HF Clinical Study for Heart Failure
The Counter HF Clinical Study for Heart Failure CAUTION: C-Pulse is an investigational device. It is limited by Federal (or United States) Law to investigational use only. 13-111-B Agenda Heart Failure
More informationWHEN TO REFER FOR ADVANCED HEART FAILURE THERAPIES
WHEN TO REFER FOR ADVANCED HEART FAILURE THERAPIES Mrudula R Munagala, M.D., FACC CO- Director Heart Failure & Circulatory Support Program OklahomaHeart.com Heart Failure Prevalence Heart Failure affects
More informationMulticenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) Long Term Outcomes
Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with (MOMENTUM 3) Long Term Outcomes Mandeep R. Mehra, MD, Daniel J. Goldstein, MD, Nir Uriel, MD, Joseph
More informationHFA- ESC criteria for Advanced HF and US Requirements for Destination Therapy
HFA- ESC criteria for Advanced HF and US Requirements for Destination Therapy ESC- HFA criteria for Adv-HF Severe symptoms of HF (NYHA class III or IV) with episodes of fluid retention and/or peripheral
More informationLeft Ventricular Assist Devices (LVADs): Overview and Future Directions
Left Ventricular Assist Devices (LVADs): Overview and Future Directions FATIMA KARAKI, M.D. PGY-3, DEPARTMENT OF MEDICINE WASHINGTON UNIVERSITY IN ST. LOUIS ST. LOUIS, MISSOURI, USA St. Louis, Missouri,
More informationVentricular Assist Devices for Permanent Therapy: Current Status and Future
Ventricular Assist Devices for Permanent Therapy: Current Status and Future Prospects Francis D. Pagani MD PhD Professor of Cardiac Surgery University of Michigan April 28 th, 2012 Disclosures NHLBI and
More informationHeart Failure 101 The Basic Principles of Diagnosis & Management
Heart Failure 101 The Basic Principles of Diagnosis & Management Bill Tran, MD Non Invasive Cardiologist February 24, 2018 What the eye does not see and the mind does not know, does not exist. DH Lawrence
More informationBETTER HEART FAILURE MANAGEMENT FROM THE COMFORT OF YOUR HOME
BETTER HEART FAILURE MANAGEMENT FROM THE COMFORT OF YOUR HOME Staying Ahead of Heart Failure with the CardioMEMS HF System The CardioMEMS HF System A UNIQUE APPROACH TO HEART FAILURE MANAGEMENT THAT CAN
More informationVentricular Assist Devices
Page 1 By Tonya Elliott, RN, MSN Background, Indications for VADs Mechanical circulatory support has become an acceptable therapy for end stage heart failure (HF) in maximally medically treated patients
More informationHeartWare ADVANCE Bridge to Transplant Trial and Continued Access Protocol Update
HeartWare ADVANCE Bridge to Transplant Trial and Continued Access Protocol Update Mark S. Slaughter, MD University of Louisville, KY, USA HeartWare Users Meeting 29 October 2012 Barcelona, Spain HEARTWARE,
More informationRamani GV et al. Mayo Clin Proc 2010;85:180-95
THERAPIES FOR ADVANCED HEART FAILURE: WHEN TO REFER Navin Rajagopalan, MD Assistant Professor of Medicine University of Kentucky Director, Congestive Heart Failure Medical Director of Cardiac Transplantation
More informationHEARTMATE 3 LEFT VENTRICULAR ASSIST SYSTEM
HEARTMATE 3 LEFT VENTRICULAR ASSIST SYSTEM A New Milestone in LVAD Therapy HeartMate 3 Left Ventricular Assist Device Introducing the new HEARTMATE 3 LVAD WITH FULL MAGLEV FLOW TECHNOLOGY HeartMate 3 LVAD
More informationVAD Program Alert: Practice Change regarding CPR
VAD Program Alert: Practice Change regarding CPR March 2018 Background The left ventricular assist device (LVAD) is a mechanical internal heart pump used to treat heart failure. The pump provides continuous
More informationOverview of MCS in Bruce B Reid, MD Surgical Director Artificial Heart Program/Heart Transplantation
Overview of MCS in 2017 Bruce B Reid, MD Surgical Director Artificial Heart Program/Heart Transplantation Technology Embracing Progress Technology Adoption Internet Adoption of Technology Pioneer in the
More informationHEARTMATE II LEFT VENTRICULAR ASSIST SYSTEM. HeartMate II Left Ventricular Assist Device
HEARTMATE II LEFT VENTRICULAR ASSIST SYSTEM HeartMate II Left Ventricular Assist Device HeartMate II Left Ventricular Assist Device UNPARALLELED REAL-WORLD EXPERIENCE Over 25,000 heart failure patients
More informationWhy Children Are Not Small Adults? Treatment of Pediatric Patients Needing Mechanical Circulatory Support
Why Children Are Not Small Adults? Treatment of Pediatric Patients Needing Mechanical Circulatory Support Utpal S Bhalala, MD, FAAP Assistant Professor and Director of Research Pediatric Critical Care
More informationAcute Circulatory Support Should We or Shouldn t We?
Acute Circulatory Support Should We or Shouldn t We? Navin K. Kapur, MD, FACC, FSCAI Assistant Professor, Division of Cardiology Director, Acute Circulatory Support Program Director, Interventional Research
More informationIntroducing the COAPT Trial
physician INFORMATION Eligible patients Symptomatic functional mitral regurgitation 3+ Not suitable candidates for open mitral valve surgery NYHA functional class II, III, or ambulatory IV Introducing
More informationThe Who, How and When of Advanced Heart Failure Therapies. Disclosures. What is Advanced Heart Failure?
The Who, How and When of Advanced Heart Failure Therapies 9 th Annual Dartmouth Conference on Advances in Heart Failure Therapies Dartmouth-Hitchcock Medical Center Lebanon, NH May 20, 2013 Joseph G. Rogers,
More informationDevice Therapy for Heart Failure
Device Therapy for Heart Failure Dr. Shelley Zieroth FRCPC Assistant Professor, Cardiology, University of Manitoba Director of Cardiac Transplant and Heart Failure Clinics St Boniface General Hospital,
More informationTri-City Cardiology Consultants FIFTH ANNUAL SYMPOSIUM
Tri-City Cardiology Consultants FIFTH ANNUAL SYMPOSIUM Faculty Disclosure Banner Baywood Medical Center -Chief of Staff FIFTH ANNUAL SYMPOSIUM NYHA class III-IV symptoms Clinical signs of fluid retention
More informationNovel Devices for End-Stage Heart Failure
Novel Devices for End-Stage Heart Failure Lynne Warner Stevenson No conflicts of interest Off-label assist devices and expanded indications will be discussed Devices for End-Stage Heart Failure New definitions
More informationHeart Failure Therapies State of the Art: 2018
Heart Failure Therapies State of the Art: 2018 Andrew J. Sauer MD Associate Professor of Medicine Division Director Advanced Heart Failure Therapies & Cardiac Transplantation University of Kansas Medical
More informationAndrew Civitello MD, FACC
Timing the Transition from Short Term to Long Term Mechanical Circulatory Support Andrew Civitello MD, FACC Medical Director, Heart Transplant Program Director, Fellowship Co-Director, Baylor St. Luke's
More informationVentricular Assist Device (VAD)
Ventricular Assist Device (VAD) Pre-operative Education Handbook FHTransplant.com 1 Table of Contents 3 Contact Information 4 Advanced Heart Failure, Cardiac Transplant and Circulatory Assist Device Program
More informationI have no disclosures. Disclosures
I have no disclosures Disclosures What is Heart Failure? Heart Failure (HF) A complex clinical syndrome where patients present with symptoms (i.e. dyspnea, fatigue, fluid retention) that result from any
More informationAdvances in Advanced Heart Failure Therapies. Disclosures. Management Algorithm for Patients in Cardiogenic Shock
Advances in Advanced Heart Failure Therapies 9 th Annual Dartmouth Conference on Advances in Heart Failure Therapies Dartmouth-Hitchcock Medical Center May 20, 2013 Joseph G. Rogers, M.D. Associate Professor
More informationCounterpulsation. John N. Nanas, MD, PhD. Professor and Head, 3 rd Cardiology Dept, University of Athens, Athens, Greece
John N. Nanas, MD, PhD Professor and Head, 3 rd Cardiology Dept, University of Athens, Athens, Greece History of counterpulsation 1952 Augmentation of CBF Adrian and Arthur Kantrowitz, Surgery 1952;14:678-87
More informationVAD come Destination therapy nell adulto con Scompenso Cardiaco
VAD come Destination therapy nell adulto con Scompenso Cardiaco Francesco Santini Division of Cardiac Surgery, IRCCS San Martino IST University of Genova Medical School, Italy Heart Transplantation is
More informationStatus of Implantable VADs
Status of Implantable VADs John V. Conte, MD, Professor of Surgery Johns Hopkins University School of Medicine Division of Cardiac Surgery The Johns Hopkins Medical Institutions Conflict of Interest Statement
More informationCase (Coding Nightmare) Current Dilemmas in Heart Failure : Closing the Gap between Clinical Care and Coding. Current Dilemmas in Heart Failure :
Current Dilemmas in Heart Failure : Closing the Gap between Clinical Care and Coding Interim Vice Chair for Clinical Affairs Department of Medicine, University of Florida 1 2 Case (Coding Nightmare) 69
More informationSTATE OF OKLAHOMA 2014 EMERGENCY MEDICAL SERVICES PROTOCOLS
5M VENTRICULAR ASSIST DEVICE (VAD) MANAGEMENT ADULT EMERGENCY MEDICAL DISPATCHER EMERGENCY MEDICAL RESPONDER EMT EMT-INTERMEDIATE 85 ADVANCED EMT PARAMEDIC A Ventricular Assist Device, or VAD, is a mechanical
More informationHeart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist
Heart Failure Management Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist Heart failure prevalence is expected to continue to increase¹ 21 MILLION ADULTS WORLDWIDE
More information3/2/2017. Identifying the Patient for Advanced Therapies. Why is Identifying the Adv HF patient important? CHF Stages and Steps of Treatment
Identifying the Patient for Advanced Therapies Cindy Bither Chief NP- Adv HF Program Medstar Heart and Vascular Institute Stage A High risk with no symptoms Stage B Structural heart disease, no symptoms
More informationGiving your heart strength. Ventricular Assist Device.
Giving your heart strength. Ventricular Assist Device. 1 National leader in Ventricular Assist Devices Although you may be nervous when considering heart surgery, you can rest assured knowing that UR Medicine
More informationLVADS IN AMBULATORY PATIENTS CLASS III PATIENT SHOULD UNDERGO LVAD IMPLANTATION
LVADS IN AMBULATORY PATIENTS CLASS III PATIENT SHOULD UNDERGO LVAD IMPLANTATION Ajith Nair MD Baylor College of Medicine / Texas Heart Institute American Association for Thoracic Surgery Mechanical Circulatory
More informationDEMYSTIFYING VADs. Nicolle Choquette RN MN Athabasca University
DEMYSTIFYING VADs Nicolle Choquette RN MN Athabasca University Objectives odefine o Heart Failure o VAD o o o o Post Operative Complications Acute Long Term Nursing Interventions What is Heart Failure?
More informationHeart Failure Therapies State of the Art 2017
Heart Failure Therapies State of the Art 2017 Andrew J. Sauer, MD Assistant Professor Director, Center for Heart Failure Medical Director, Heart Transplantation UNOS Primary Transplant Physician asauer@kumc.edu
More informationSurgery and device intervention for the elderly with heart failure: assessing the need. Devices and Technology for heart failure in 2011
Surgery and device intervention for the elderly with heart failure: assessing the need Devices and Technology for heart failure in 2011 Assessing cardiovascular function / prognosis (in the elderly): composite
More information1/21/2016. HeartMate II Indications for Use. Ventricular Assist Device Overview. Jon G. Echterling MSN, CCRN, FNP-BC. Learning Objectives
Ventricular Assist Device Overview Jon G. Echterling MSN, CCRN, FNP-BC February 5, 2016 Learning Objectives Identify the components and operation of the HeartMate II LVAD Describe the path blood follows
More information2/3/2017. Objectives. Effective Heart Failure Management through Evidence Based Practice and Innovation
Effective Heart Failure Management through Evidence Based Practice and Innovation Jennifer Bauerly RN, CHFN, APRN-BC CentraCare Heart and Vascular Center Objectives Describe the scope and impact of heart
More informationMcHenry Western Lake County EMS System Paramedic, EMT-B and PHRN Continuing Education Packet January-Feb 2018 Ventricular Assist Devices
McHenry Western Lake County EMS System Paramedic, EMT-B and PHRN Continuing Education Packet January-Feb 2018 Ventricular Assist Devices Simply a ventricular assist device (VAD) is an implantable mechanical
More informationDo we really need an Artificial Heart? No!! John V. Conte, MD, Professor of Surgery Johns Hopkins University School of Medicine
Do we really need an Artificial Heart? No!! John V. Conte, MD, Professor of Surgery Johns Hopkins University School of Medicine Division of Cardiac Surgery The Johns Hopkins Medical Institutions Conflict
More informationLess Invasive Ventricular Enhancement For Heart Attack Patients. Revivent TC TransCatheter Ventricular Enhancement System
For Heart Attack Patients Revivent TC TransCatheter Ventricular Enhancement System This patient booklet is for those who have suffered a heart attack resulting in damage to the left side of the heart causing
More informationCARDIOMEMS HF SYSTEM HOW TO STAY ABOVE HEART FAILURE: TALKING TO YOUR PATIENT ABOUT THE
CARDIOMEMS HF SYSTEM HOW TO STAY ABOVE HEART FAILURE: TALKING TO YOUR PATIENT ABOUT THE CARDIOMEMS HF SYSTEM This overview of clinical workflow best practices and patient talking points is based on in-depth
More informationHeart Failure: Combination Treatment Strategies
Heart Failure: Combination Treatment Strategies M. McDonald MD, FRCP State of the Heart Symposium May 28, 2011 None Disclosures Case 69 F, prior MIs (LV ejection fraction 25%), HTN No demonstrable ischemia
More informationเอกราช อร ยะช ยพาณ ชย
30 July 2016 เอกราช อร ยะช ยพาณ ชย Heart Failure and Transplant Cardiology aekarach.a@chula.ac.th Disclosure Speaker, CME service: Merck, Otsuka, Servier Consultant, non-cme service: Novartis, Menarini
More informationNeprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary
Neprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1 Indication Entresto Reduce the risk of cardiovascular (sacubitril/valsartan) death
More informationHeart Failure: Guideline-Directed Management and Therapy
Heart Failure: Guideline-Directed Management and Therapy Guideline-Directed Management and Therapy (GDMT) was developed by the American College of Cardiology and American Heart Association to define the
More informationDiagnosis of Device Thrombosis
Diagnosis of Device Thrombosis Andrew Civitello MD, FACC Medical Director, Heart Transplant Program Director, Fellowship Co-Director, Baylor St. Luke's Medical Center / Texas Heart Institute Trends in
More informationThe Interface of Cardiology and Palliative Medicine
The Interface of Cardiology and Palliative Medicine Nathan Goldstein, MD Associate Professor Hertzberg Palliative Care Institute Brookdale Department of Geriatrics and Palliative Medicine Mount Sinai School
More information2018 Update on Heart Failure Management. Where we are today.
2018 Update on Heart Failure Management Where we are today. Mitchell Saltzberg, MD Medical Director Comprehensive Heart Failure and Transplant Program HEART FAILURE 1 Current State of Heart Failure 5.7M
More informationStage D Heart Failure. Eric Adler MD Associate Clinical Professor of Medicine Medical Director Cardiac Transplantation
Stage D Heart Failure Eric Adler MD Associate Clinical Professor of Medicine Medical Director Cardiac Transplantation What are the Stages of HF Stage Description Treatment A At risk for HF B Structural
More informationLeft Ventricular Assist Devices LVAD. North Country EMS Program Agency 3/21/12
Left Ventricular Assist Devices LVAD North Country EMS Program Agency 3/21/12 Objectives Describe indications for and functions of ventricular assist devices (LVAD) Differentiate assessment findings of
More informationDISCLOSURES ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION NONE
ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION Lori M. Tam, MD Providence Heart Institute DISCLOSURES NONE 1 OUTLINE Systolic vs. Diastolic Heart Failure New
More informationManagement Strategies for Advanced Heart Failure
Management Strategies for Advanced Heart Failure Mary Norine Walsh, MD, FACC Medical Director, HF and Cardiac Transplantation St Vincent Heart Indianapolis, IN USA President American College of Cardiology
More informationEnd Stage Heart Failure - Time to Bring the Hammer Down
End Stage Heart Failure - Time to Bring the Hammer Down Eric R. Skipper, MD, FACS Chief, Adult Cardiovascular Surgery Surgical Director of Cardiac Transplantation and Mechanical Circulatory Support 2 3
More informationSummary/Key Points Introduction
Summary/Key Points Introduction Scope of Heart Failure (HF) o 6.5 million Americans 20 years of age have HF o 960,000 new cases of HF diagnosed annually o 5-year survival rate for HF is ~50% Classification
More informationFacts. STRONG Risk Factors for HF* LVAD, BiVAD, RVAD, HVAD 10/21/ million adults in the US have heart failure.
10/21/18 1 Facts 5.8 million adults in the US have heart failure. About ½ of those who have HF have a 5 year life expectancy. STRONG Risk Factors for HF* Coronary Heart Disease/MI/Afib COPD Renal Failure
More informationIs a LVAD the Right Treatment for Me? Decision Aid
Is a LVAD the Right Treatment for Me? Decision Aid patienteducation.osumc.edu 2 Making an Informed Decision Review this book We give you this information to help you understand what the LVAD treatment
More informationHeart Failure Update John Coyle, M.D.
Heart Failure Update 2011 John Coyle, M.D. Causes of Heart Failure Anderson,B.Am Heart J 1993;126:632-40 It It is now well-established that at least one-half of the patients presenting with symptoms and
More informationModule 1: Evidence-based Education for Health Care Professionals
Module 1: Evidence-based Education for Health Care Professionals Heart Failure is a HUGE Problem Prevalence Incidence Mortality Hospital Discharges Cost 1 5,300,000 660,000 284,965 1,084,000 $34.8 billion
More informationState-of-the-Art Management of Chronic Systolic Heart Failure
State-of-the-Art Management of Chronic Systolic Heart Failure Michael McCulloch, MD 17 th Annual Cardiovascular Update Intermountain Medical Center December 16, 2017 Disclosures: I have no financial disclosures
More informationHeart Failure Update. Bibiana Cujec MD May 2015
Heart Failure Update Bibiana Cujec MD May 2015 Disclosures Participation in clinical trial GUIDE IT (BNP in management of HF) Plan Review of new trials/ccs guidelines Management of heart failure: cases
More informationLEARNING ABOUT HEART FAILURE A B C D
LEARNING ABOUT HEART FAILURE Heart failure is a debilitating and potentially life-threatening condition, affecting around 26 million people worldwide however few people fully understand heart failure WHAT
More informationMechanical Circulatory Support (MCS): What Every Pharmacist Needs to Know!
Mechanical Circulatory Support (MCS): What Every Pharmacist Needs to Know! Matthew A. Wanat, PharmD, BCPS, BCCCP, FCCM Clinical Assistant Professor University of Houston College of Pharmacy Clinical Pharmacy
More informationCombination of renin-angiotensinaldosterone. how to choose?
Combination of renin-angiotensinaldosterone system inhibitors how to choose? Karl Swedberg Professor of Medicine Sahlgrenska Academy University of Gothenburg karl.swedberg@gu.se Disclosures Research grants
More informationThe ACC Heart Failure Guidelines
The ACC Heart Failure Guidelines Fakhr Alayoubi, Msc,R Ph President of SCCP Cardiology Clinical Pharmacist Assistant Professor At King Saud University King Khalid University Hospital Riyadh-KSA 2017 ACC/AHA/HFSA
More informationEMS: Care of the VAD Patient. Brittany Butzler BSN RN VAD Coordinator Froedtert and the Medical College of WI
EMS: Care of the VAD Patient Brittany Butzler BSN RN VAD Coordinator Froedtert and the Medical College of WI Disclosure No relevant financial relationships by planners or presenters Left Ventricular Assist
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Cardiogenic Shock Mechanical Support Eulàlia Roig FESC Heart Failure and HT Unit Hospital Sant Pau - UAB Barcelona. Spain No conflics of interest Mechanical Circulatory
More informationReferral for Heart Transplantation - who and when?
Transplant Referral for heart transplantation - who and when Sarah Fitzsimons Chairs: Kathy Ferrier & Richard Troughton Referral for Heart Transplantation - who and when? CSANZ June 2018 1 Introduction
More informationMedical Therapy after LVAD
Medical Therapy after LVAD Maria Frigerio 2nd Section of Cardiology, Heart Failure & Cardiac Transplant Unit DeGasperis CardioCenter, Niguarda Hospital, Milan, Italy Heart failure therapy in LVAD pts A
More informationMartin R Cowie Professor of Cardiology, National Heart & Lung Institute Imperial College London (Royal Brompton Hospital)
Treatment of Sleep-Disordered Breathing With Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure and Reduced Ejection Fraction (SERVE-HF) Martin R Cowie Professor
More informationTreating HF Patients with ARNI s Why, When and How?
Treating HF Patients with ARNI s Why, When and How? 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La Jolla, CA Barry Greenberg M.D. Distinguished Professor
More informationAcute heart failure: ECMO Cardiology & Vascular Medicine 2012
Acute heart failure: ECMO Cardiology & Vascular Medicine 2012 Lucia Jewbali cardiologist-intensivist 14 beds/8 ICU beds Acute coronary syndromes Heart failure/ Cardiogenic shock Post cardiotomy Heart
More informationImplantable Ventricular Assist Devices and Total Artificial Hearts. Policy Specific Section: June 13, 1997 March 29, 2013
Medical Policy Implantable Ventricular Assist Devices and Total Artificial Hearts Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Surgery Original Policy Date: Effective
More informationKnowing your treatment options can give you hope for a longer, better life
Heart failure is a deadly disease Knowing your treatment options can give you hope for a longer, better life With heart failure, it was not a matter of if I would get worse; it was a matter of when, and
More informationPolicy Specific Section: May 16, 1984 April 9, 2014
Medical Policy Heart Transplant Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Transplant Original Policy Date: Effective Date: May 16, 1984 April 9, 2014 Definitions
More informationEstimated 5.7 million Americans with HF. 915, 000 new HF cases annually, HF incidence approaches
Heart Failure: Management of a Chronic Disease Jenny Bauerly RN, CHFN, APRN-BC Heart Failure (HF) Definition A complex clinical syndrome that can result from any structural or functional cardiac disorder
More informationCARDIOMEMS HF SYSTEM PATIENT MANAGEMENT CLINICAL QUICK GUIDE
CARDIOMEMS HF SYSTEM PATIENT MANAGEMENT CLINICAL QUICK GUIDE CLINICAL QUICK GUIDE CARDIOMEMS HF SYSTEM Information in this Clinical Quick Guide is based on: In-depth clinician feedback 1 on the common
More informationModule 1: Evidence-based Education for Health Care Professionals
Module 1: Evidence-based Education for Health Care Professionals Heart Failure is a HUGE Problem Prevalence Incidence Mortality Hospital Discharges Cost 1 5,300,000 660,000 284,965 1,084,000 $34.8 billion
More informationWhat s new in heart failure management? Yonsei Cardiovascular Center Yonsei University College of Medicine
What s new in heart failure management? Yonsei Cardiovascular Center Yonsei University College of Medicine Current Guideline of Treatment Asymptomatic Mild/Mod Severe Refractory Correct Cause: Arrhythmias
More information